Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 677 press releases before 2019
-
Onglyza becomes the first DPP4 inhibitor available for use in Europe in Type 2 Diabetes patients with moderate or severe renal impairment
-
ONGLYZA™ US label update provides further evidence regarding use in renally impaired adults with type 2 diabetes
-
AstraZeneca and Targacept initiate phase IIB clinical trial of TC-5214 as a switch monotherapy treatment for major depressive disorder
-
AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer
-
US FDA assigns new PDUFA date for BRILINTA (ticagrelor tablets)
-
European Commission approves nasal spray vaccine FLUENZ for the prevention of seasonal influenza in children
-
AstraZeneca PLC Fourth Quarter and Full Year Results 2010
-
AstraZeneca Replies To The US FDA Complete Response Letter For BRILINTA (Ticagrelor Tablets)
-
US Food and Drug Administration extend review timeline for vandetanib new drug application
-
AstraZeneca and Abbott end license agreement for the development of Certriad
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
